As of 2025-07-12, the EV/EBITDA ratio of Kiniksa Pharmaceuticals Ltd (KNSA) is -133.02. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KNSA's latest enterprise value is 1,892.60 mil USD. KNSA's TTM EBITDA according to its financial statements is -14.23 mil USD. Dividing these 2 quantities gives us the above KNSA EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 5.3x - 7.9x | 6.6x |
| Forward P/E multiples | 5.3x - 7.9x | 6.6x |
| Fair Price | 1.12 - 0.61 | 0.87 |
| Upside | -96.0% - -97.8% | -96.9% |
| Date | EV/EBITDA |
| 2025-07-11 | -133.02 |
| 2025-07-10 | -137.43 |
| 2025-07-09 | -136.66 |
| 2025-07-08 | -128.51 |
| 2025-07-07 | -132.30 |
| 2025-07-03 | -131.94 |
| 2025-07-02 | -129.69 |
| 2025-07-01 | -128.66 |
| 2025-06-30 | -130.87 |
| 2025-06-27 | -132.76 |
| 2025-06-26 | -135.07 |
| 2025-06-25 | -134.51 |
| 2025-06-24 | -137.99 |
| 2025-06-23 | -136.25 |
| 2025-06-20 | -134.81 |
| 2025-06-18 | -132.20 |
| 2025-06-17 | -132.30 |
| 2025-06-16 | -134.66 |
| 2025-06-13 | -134.10 |
| 2025-06-12 | -131.17 |
| 2025-06-11 | -143.94 |
| 2025-06-10 | -141.64 |
| 2025-06-09 | -144.51 |
| 2025-06-06 | -143.99 |
| 2025-06-05 | -140.35 |
| 2025-06-04 | -137.07 |
| 2025-06-03 | -138.25 |
| 2025-06-02 | -132.15 |
| 2025-05-30 | -129.28 |
| 2025-05-29 | -128.35 |
| 2025-05-28 | -128.76 |
| 2025-05-27 | -124.81 |
| 2025-05-23 | -126.86 |
| 2025-05-22 | -122.04 |
| 2025-05-21 | -122.92 |
| 2025-05-20 | -125.89 |
| 2025-05-19 | -126.10 |
| 2025-05-16 | -123.58 |
| 2025-05-15 | -121.63 |
| 2025-05-14 | -117.33 |
| 2025-05-13 | -120.25 |
| 2025-05-12 | -126.61 |
| 2025-05-09 | -122.45 |
| 2025-05-08 | -125.99 |
| 2025-05-07 | -126.25 |
| 2025-05-06 | -127.12 |
| 2025-05-05 | -131.43 |
| 2025-05-02 | -130.76 |
| 2025-05-01 | -131.22 |
| 2025-04-30 | -127.28 |